Tier 3 — preclinical

Therapeutic and pharmacological effects of quercetin in autoimmune diseases: a systematic review of preclinical and clinical evidence

May Xin Cheong, Joen Wen Hui Lee, Mei Qian Yau
Immunologic research 2026 74(1):73

Bibliography

PubMed
PMID 42467366
DOI
10.1007/s12026-026-09809-8
Funding
Indexed grant support: FRGS/1/2023/SKK06/TAYLOR/03/2 — Ministry of Higher Education, Malaysia. The indexed list may not contain the complete funding declaration.
Competing interests
Reported disclosure: Declarations. Competing interests: The authors declare no competing interests.

Study snapshot

DesignSystematic review of clinical and human-cell autoimmune research
ModelMixed human and preclinical evidence synthesis
Sample13 studies in qualitative synthesis
InterventionQuercetin interventions and human-derived cell exposures
DurationEligible studies from 2014 onward
EndpointsInflammatory measures; Protein activity, binding or signaling

What the study showed, in plain terms

Published in 2026, this source examined inflammation and clinical symptoms. Design: Systematic review of clinical and human-cell autoimmune research. Sample/model: 13 studies in qualitative synthesis. The exposure or intervention was Quercetin interventions and human-derived cell exposures. Follow-up or treatment period: Eligible studies from 2014 onward.

The review describes inflammatory and signaling effects and favorable findings in a small number of clinical reports.

Human-derived cell models are preclinical evidence, not patient trials. Heterogeneous designs and limited controlled clinical data prevent broad autoimmune-treatment conclusions.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Immune Health, Colds and COVID-19. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • The review describes inflammatory and signaling effects and favorable findings in a small number of clinical reports.
  • The recorded outcome domains were Inflammatory measures; Protein activity, binding or signaling.
  • The result applies to the tested exposure: Quercetin interventions and human-derived cell exposures; Eligible studies from 2014 onward.

What this study can and cannot tell us

  • Human-derived cell models are preclinical evidence, not patient trials. Heterogeneous designs and limited controlled clinical data prevent broad autoimmune-treatment conclusions.
  • Cell concentrations, species, disease models and experimental routes cannot be converted directly into an effective or safe oral human regimen.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology